ANDS: In general, faster is better when it comes to getting to undetectable virus, so ANA598 did show some benefit relative to the control arm in this regard. But will this be sufficient to allow ANDS to find a dose where ANA598 is potent enough to significantly improve on the SoC SVR rate and also be tolerable?
Given the severe rash seen in phase-1b and the continuing rash problem seen to a lesser degree in phase-2 to date, I have my doubts.
Market Data 
Markets 
AI
